首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   248208篇
  免费   13047篇
  国内免费   6948篇
耳鼻咽喉   2793篇
儿科学   8917篇
妇产科学   3155篇
基础医学   19027篇
口腔科学   4449篇
临床医学   32807篇
内科学   47729篇
皮肤病学   3130篇
神经病学   11419篇
特种医学   13295篇
外国民族医学   22篇
外科学   36149篇
综合类   22963篇
现状与发展   26篇
一般理论   6篇
预防医学   15554篇
眼科学   4730篇
药学   25380篇
  97篇
中国医学   5030篇
肿瘤学   11525篇
  2023年   2376篇
  2022年   4772篇
  2021年   11336篇
  2020年   6143篇
  2019年   11937篇
  2018年   6562篇
  2017年   5580篇
  2016年   7489篇
  2015年   10548篇
  2014年   19483篇
  2013年   17145篇
  2012年   20036篇
  2011年   17020篇
  2010年   15574篇
  2009年   15267篇
  2008年   13882篇
  2007年   13888篇
  2006年   11813篇
  2005年   7980篇
  2004年   4279篇
  2003年   3759篇
  2002年   3025篇
  2001年   2409篇
  2000年   2207篇
  1999年   1497篇
  1998年   1892篇
  1997年   1775篇
  1996年   1484篇
  1995年   1453篇
  1994年   1442篇
  1993年   1118篇
  1992年   1368篇
  1991年   1203篇
  1990年   1274篇
  1989年   1189篇
  1988年   1142篇
  1987年   976篇
  1986年   823篇
  1985年   1764篇
  1984年   1951篇
  1983年   1405篇
  1982年   1480篇
  1981年   1457篇
  1980年   1271篇
  1979年   1090篇
  1978年   838篇
  1977年   831篇
  1976年   740篇
  1975年   499篇
  1974年   510篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
背景 呼吸道合胞病毒(RSV)毛细支气管炎易出现反复喘息,且下呼吸道分泌物中半胱氨酸白三烯(CysLTs)水平升高。而孟鲁司特是一种白三烯受体拮抗剂,关于其治疗RSV毛细支气管炎症状的研究相对较少。目的 探讨孟鲁司特改善婴幼儿RSV毛细支气管炎后症状及减轻反复喘息发作的有效性和安全性。方法 2015年6月-2017年6月连续纳入在潍坊市妇幼保健院出院的RSV毛细支气管炎患儿,随机分为治疗组、对照组。Ⅰ期,治疗组:口服孟鲁司特颗粒(4 mg)12周,1次/d;对照组:口服安慰剂12周,1次/d。对两组无症状天数、个人日记评分进行评估。随访9个月(Ⅱ期),观察Ⅰ+Ⅱ期反复喘息人数和医疗资源应用情况等。依据意向性分析(ITT)原则,应用全分析集(FAS)分析数据。结果 共纳入研究对象186例,治疗组92例,对照组94例。治疗组完成Ⅰ期研究的患儿为89例,对照组为90例;治疗组完成Ⅰ+Ⅱ期的患儿为84例,对照组为86例。治疗组平均依从性为97.8%(7 560/7 728),对照组平均依从性为97.4%(7 690/7 896),两组患儿平均依从性比较,差异无统计学意义(χ2=3.16,P=0.07)。在Ⅰ期研究期间,两组无症状天数、日间无症状天数、夜间无症状天数、个人日记评分比较,差异均无统计学意义(P>0.05)。在整个研究过程中(Ⅰ+Ⅱ期),治疗组RSV毛细支气管炎喘息复发人数少于对照组(P<0.05),治疗组喘息患儿出现2次及以上喘息比例低于对照组(χ2=5.14,P=0.02)。Ⅰ+Ⅱ期研究期间治疗组医疗资源应用人数、β-受体激动剂应用人数、糖皮质激素应用人数、住院人数低于对照组(P<0.05)。在事后亚组分析中,治疗组有湿疹史与父母哮喘史的患儿中无症状天数〔(49.7±20.2)、(51.3±20.9)d〕多于对照组〔(36.3±20.4)、(37.8±19.3)d〕(t=2.19,P=0.03;t=2.24,P=0.03)。整个研究过程中没有患儿因不良反应退出研究,两组间胃肠道紊乱、皮疹、转氨酶升高发生率比较,差异均无统计学意义(χ2=0.23,P=0.63;χ2=0.03,P=0.86;χ2=0.15,P=0.69)。结论 口服孟鲁司特(4 mg)12周不能改善RSV毛细支气管炎患儿呼吸道症状,但能降低患儿反复喘息发作次数。口服孟鲁司特(4 mg)有一定效果且安全。  相似文献   
82.
Esophageal adenocarcinoma is the fastest rising cancer in the United States. It develops from long‐standing gastroesophageal reflux disease which affects >20% of the general population. It carries a very poor prognosis with 5‐year survival <20%. The disease is known to sequentially progress from reflux esophagitis to a metaplastic precursor, Barrett''s esophagus and then onto dysplasia and esophageal adenocarcinoma. However, only few patients with reflux develop Barrett''s esophagus and only a minority of these turn malignant. The reason for this heterogeneity in clinical progression is unknown. To improve patient management, molecular changes which facilitate disease progression must be identified. Animal models can provide a comprehensive functional and anatomic platform for such a study. Rats and mice have been the most widely studied but disease homology with humans has been questioned. No animal model naturally simulates the inflammation to adenocarcinoma progression as in humans, with all models requiring surgical bypass or destruction of existing antireflux mechanisms. Valuable properties of individual models could be utilized to holistically evaluate disease progression. In this review paper, we critically examined the current animal models of Barrett''s esophagus, their differences and homologies with human disease and how they have shaped our current understanding of Barrett''s carcinogenesis.  相似文献   
83.
 Û   ¬  ࿞ ¿   ¬ í  &#x; ྽   &#x;         &#x; 《中国肺癌杂志》2021,24(3):161
背景与目的以免疫检查点抑制剂(immune checkpoint inhibitors, ICIs)为代表的免疫治疗越来越广泛地应用于肺癌治疗。然而,对于程序性死亡受体配体1(programmed cell death-ligand 1, PD-L1)高表达,即肿瘤比例评分(tumor proportion score, TPS)≥50%的晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)患者,采用单纯免疫治疗还是免疫联合化疗在临床上仍存争议。本研究旨在评估PD-L1高表达的晚期NSCLC患者接受单纯免疫治疗与免疫联合化疗的疗效。方法本研究回顾性分析了49例PD-L1高表达晚期NSCLC患者的临床资料。PD-L1表达采用22C3抗体行免疫组化染色,按TPS判读PD-L1表达水平。比较不同临床特征分组患者的客观缓解率(objective response rate,ORR)和无进展生存时间(progression free survival, PFS)。结果免疫单药与免疫联合化疗组的ORR分别为47.1%(8/17)和43.8%(14/32),差异无统计学意义(P=0.825)。免疫单药与免疫联合化疗组的中位PFS分别为8.0个月和6.8个月,差异无统计学意义(P=0.502)。并对本组PD-L1高表达患者免疫治疗的预测因素进行了分析,结果显示,一线免疫治疗ORR(12/19, 63.2%)显著优于二线及以上免疫治疗(10/30, 33.3%),差异有统计学意义(P=0.041),二者间PFS无差异。年龄、性别、吸烟史、功能状态评分(performance status, PS)、病理类型、肿瘤大小、肿瘤淋巴结转移(tumor node metastasis, TNM)分期与ORR和PFS不相关。结论PD-L1高表达的晚期NSCLC患者接受免疫单药和免疫联合化疗的疗效相近。PD-L1高表达患者一线免疫治疗的ORR更佳。对此类人群的最佳治疗方案有待于前瞻性临床研究进一步探索。  相似文献   
84.
《Clinical neurophysiology》2021,132(12):3104-3115
ObjectiveWe aimed to establish an objective neurophysiological test protocol that can be used to assess the somatosensory nervous system.MethodsIn order to assess most fiber subtypes of the somatosensory nervous system, repetitive stimuli of seven different modalities (touch, vibration, pinprick, cold, contact heat, laser, and warmth) were synchronized with the electroencephalogram (EEG) and applied on the cheek and dorsum of the hand and dorsum of the foot in 21 healthy subjects and three polyneuropathy (PNP) patients. Latencies and amplitudes of the modalities were assessed and compared. Patients received quantitative sensory testing (QST) as reference.ResultsWe found reproducible evoked potentials recordings for touch, vibration, pinprick, contact-heat, and laser stimuli. The recording of warm-evoked potentials was challenging in young healthy subjects and not applicable in patients. Latencies were shortest within Aβ-fiber-mediated signals and longest within C-fibers. The test protocol detected function loss within the Aβ-fiber and Aδ-fiber-range in PNP patients. This function loss corresponded with QST findings.ConclusionIn this pilot study, we developed a neurophysiological test protocol that can specifically assess most of the somatosensory modalities. Despite technical challenges, initial patient data appear promising regarding a possible future clinical application.SignificanceEstablished and custom-made stimulators were combined to assess different fiber subtypes of the somatosensory nervous system using modality-specific evoked potentials.  相似文献   
85.
改良超滤(MUF)技术作为心肺转流中节约用血的重要手段之一,具有浓缩血液、清除炎性介质、减轻组织水肿等优点,但随着微小化体外循环技术的应用,MUF在临床应用中的获益性和必要性开始受到各中心的重新审视。本文对近年来MUF的临床使用进展予以综述。  相似文献   
86.
《Clinical neurophysiology》2019,130(12):2231-2237
ObjectiveThe clinical and neurophysiological characteristics of myoclonus in Angelman syndrome (AS) have been evaluated in single case or small cohorts, with contrasting results. We evaluated the features of myoclonus in a wide cohort of AS patients.MethodsWe performed polygraphic EEG-EMG recording in 24 patients with genetically confirmed AS and myoclonus. Neurophysiological investigations included jerk-locked back-averaging (JLBA), cortico-muscular coherence (CMC) and generalised partial directed coherence (GPDC). CMC and GPDC analyses were compared to those obtained from 10 healthy controls (HC).ResultsTwenty-four patients (aged 3–35 years, median 20) were evaluated. Sequences of quasi-continuous rhythmic jerks mostly occurred at alpha frequency or just below (mean 8.4 ± 1.4 Hz), without EEG correlate. JLBA did not show any clear transient preceding the jerks. CMC showed bilateral over-threshold CMC in alpha band that was prominent on the contralateral hemisphere in the patient group as compared to HC group. GPDC showed a significantly higher alpha outflow from both hemispheres toward activated muscles in the patient group, and a significantly higher beta outflow from contralateral hemisphere in the HC group.ConclusionsThese neurophysiological findings suggest a subcortical generator of myoclonus in AS.SignificanceMyoclonus in AS has not a cortical origin as previously hypothesised.  相似文献   
87.
目的 探讨小儿弯刀综合征的诊断、外科治疗方法及治疗后的近、中期结果。方法 回顾性分析2010年1月到2017年12月手术治疗的14例弯刀综合征的临床资料。其中,男7例,女7例;年龄(18.23±28.55)个月,范围在23 d至9岁。合并其他心血管畸形10例,中位心8例,右肺发育不良7例,有侧支循环8例,合并肺动脉高压10例。用SPSS 16.0软件的寿命表(Life Table)做出本组患儿术后生存曲线,评估其近、中期生存状况。结果 9例异常肺静脉(scimitar vein,SV)从下腔静脉切下,端-侧吻合于左心房;SV分成2支2例,1例采用2支SV连同部分下腔静脉壁切下,另1例2支SV从下腔静脉从根部切下侧-侧吻合形成单根SV,均吻合于左心房;SV离左心房距离过大3例,2例将SV吻合在右心房右侧壁,再重建心房间隔,1例SV与自体心包卷管道连接再吻合于左心房。其他心血管畸形同期手术矫治。8例有侧支循环,3例心导管检查时被封堵,5例手术时切断缝合。本组14例手术死亡2例(14.29%),另有1例于术后1年2个月因肺炎、呼吸衰竭死亡。本组术后1、3、5年累积生存率分别为86%、73%和73%。术后出院时有1例移植的SV开口狭窄,血流速度为1.9 m/s;有3例随访期间发现移植SV狭窄,血流速度超过1.6 m/s。结论 弯刀综合征可合并其他心血管畸形、中位心、右肺发育不良等。一般将SV与左心房吻合;SV离左心房距离大或多条SV时,可采用个性化办法将SV吻合于左心房。侧支循环心导管检查时可封堵,或术中切断缝合。  相似文献   
88.
目的 探讨PDCA 循环在消化道肿瘤伴糖尿病患者营养全程管理中的效果观察。方法 运用PDCA循环对80例不同程度营养不良的消化道肿瘤伴糖尿病患者实施营养全程管理,比较干预前后患者的体重、BMI指数、糖化血红蛋白、血红蛋白、总蛋白、白蛋白及球蛋白水平。结果 患者血红蛋白、总蛋白、白蛋白及球蛋白水平均有提高,比较差异均有统计学意义(P<0.05)。结论 PDCA循环管理在消化道肿瘤伴糖尿病患者营养全程管理中有较大的优势, 值得推广。  相似文献   
89.
90.

Background

Arterial vascular anomalies in patients undergoing kidney transplantation (KT) are correlated with a higher incidence of early surgical complications, potentially causing graft loss. Arterial reconstruction allows patients to overcome these surgical challenges, thus minimizing the risk of poor outcomes. The aim of the present study is to retrospectively investigate the safety and effectiveness of the multiple arterial reconstruction technique with a Teflon patch in case of an unavailable aortic patch: to do so, surgical complications, graft function, and patient survival were evaluated.

Methods

During the period January 2009 to August 2016, 202 adult deceased-donor KTs were performed at our center. Group A (n = 27; reconstruction of multiple arteries) and Group B (n = 175; control group) were compared.

Results

No differences were observed between the 2 groups in terms of early postoperative course, with no vascular complication observed in Group A. No vascular patch infections were reported, nor longer cold ischemia time rates. Similarly, long-term survival rates were similar between the 2 groups.

Conclusions

The Teflon-patch arterial reconstruction technique appears to be safe and effective, with an acceptable balance of benefits and potential risks of using a prosthetic material. Studies based on larger series are needed to further validate this approach.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号